ClinicalTrials.gg
CompletedNCT07262346Updated Sep 21, 2026

The Phase Ⅰd Clinical Trial of Hydronidone Capsules

A Phase 1 interventional study of Hydronidone capsules and Placebo capsules in Liver Fibrosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Enrollment
59th of 127
138 · median 120
Started
2025
with 18 others
Phase 1
11 of 214
2 open now
Registered
184th of 214
by date
Lead sponsor
6 of 214
Beijing Continent Pharmaceutical Co, Ltd.

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 59th largest by enrollment of the 127 interventional ones that give a count, is one of 19 that started in 2025, is one of 11 in phase 1, and was the 184th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

Based on the Phase I (Ia, Ib, Ic) clinical pharmacokinetic study of Hydronidone Capsules, a clinical pharmacokinetic trial of Hydronidone Capsules (specification: 30 mg/capsule) was conducted, including single-dose administration, multiple-dose administration, and a food-effect study. The aim was to investigate the safety, tolerability, and pharmacokinetic characteristics of higher doses of Hydronidone Capsules (specification: 30 mg/capsule) in healthy subjects, in preparation for future expansion of indications.

03

Conditions studied

  • Liver Fibrosis

Browse trials for

Keywords

  • Hydronidone
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects, both male and female;
  2. Age: 18-45 years;
  3. Weight: Male ≥50 kg, Female ≥45 kg, with a between 19 and 26 (BMI = weight (kg)/height² (m²));
  4. Pass a comprehensive health examination, meaning no abnormalities or no findings in the following: vital signs, physical examination, blood and urine routine tests, blood pregnancy test, blood glucose, blood lipids, blood electrolytes, surface antigen, liver and kidney function, , and syphilis antibody tests, 12-lead , nicotine screening, urine drug screening, alcohol breath test, chest X-ray, etc.;
  5. Have been fully informed about the nature, significance, potential benefits, possible inconveniences, and risks of the study prior to participation, and voluntarily agree to take part in this clinical trial. Subjects must be able to communicate well with the researchers, comply with all study requirements, and have the capacity to understand and sign the written form.

Exclusion criteria

Exclusion Criteria:

  1. (Inquiry) Participation in any other clinical trial within three months prior to this study;
  2. (Inquiry) Presence of any disease that may affect the safety of the trial or the pharmacokinetics of the drug, including but not limited to: past or current diseases of the heart, liver, kidneys, endocrine system, digestive tract, immune system, respiratory system, nervous system, or psychiatric disorders [particularly cardiovascular diseases or individuals at risk of cardiovascular diseases, any gastrointestinal diseases affecting drug absorption (e.g., irritable bowel syndrome, inflammatory bowel disease), active pathological bleeding (e.g., peptic ulcer), urticaria, epilepsy, allergic rhinitis, eczematous dermatitis, asthma, active tuberculosis, etc.];
  3. (Inquiry) Allergic constitution: such as a history of drug or food allergies, skin allergies, or lactose intolerance;
  4. (Inquiry) Use of any drugs that inhibit or induce hepatic drug metabolism within 28 days before taking the drug (common enzyme inducers: barbiturates such as phenobarbital, carbamazepine, aminoglutethimide, griseofulvin, meprobamate, phenytoin, glutethimide, rifampicin, dexamethasone; common enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamides);
  5. Use of any medications (including herbal medicines) or health products within 14 days before the first dose;
  6. (Inquiry) Individuals with special dietary requirements who cannot adhere to a standardized diet (e.g., intolerance to standard meals) or those with difficulty swallowing;
  7. (Inquiry) Inability to tolerate venipuncture and/or a history of blood or needle phobia;
  8. (Inquiry) Habitual excessive consumption of tea, coffee, or caffeine-containing beverages (more than 8 cups per day, 1 cup = 250 mL); or consumption of any caffeine-containing foods or beverages (e.g., coffee, strong tea, chocolate, etc.) within 48 hours before the first dose, or adherence to any special diet that may affect drug absorption, distribution, metabolism, or excretion;
  9. (Inquiry) History of excessive alcohol consumption (defined as more than 28 standard units per week for men and more than 21 standard units per week for women (1 standard unit contains 14 g of alcohol, equivalent to 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine)); or regular alcohol consumption (more than 14 standard units per week) within 6 months prior to the trial; or consumption of any alcohol-containing products within 24 hours before the first dose;
  10. (Inquiry) Blood donation or significant blood loss (exceeding 450 mL) within 3 months before the first dose, or plans to donate blood or blood components during the study or within 3 months after its completion;
  11. (Inquiry) Occurrence of an acute illness during the pre-study screening phase or before administration of the study drug;
  12. (Inquiry) Consumption of any foods or beverages known to induce or inhibit hepatic metabolic enzymes (e.g., grapefruit, mango, dragon fruit, grape juice, orange juice, etc., which are rich in flavonoids or citrus glycosides) within 24 hours before the first dose;
  13. (Inquiry) Surgery within three months before screening or plans to undergo surgery during the study period;
  14. (Inquiry) History of drug abuse or substance abuse;
  15. (Inquiry) Smoking more than 5 cigarettes per day within 14 days before screening, or inability to discontinue the use of any tobacco products during the trial period;
  16. (Inquiry) Smoking or use of any tobacco products between screening and hospital admission;
  17. Positive nicotine test result;
  18. Alcohol breath test result greater than 0.0 mg/100 mL;
  19. Positive urine drug screen result;
  20. Pregnant or breastfeeding women;
  21. Individuals planning to conceive within 6 months after the trial or unwilling to use non-pharmacological measures;
  22. Any condition deemed by the investigator as potentially affecting the subject's ability to provide , comply with the trial protocol, or participate in the trial in a way that could impact the results or subject safety.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    SAD:180mg drug group

    On the morning of D1, the patients took 180mg of hydronidone capsules orally on an empty stomach once.

    Drug: Hydronidone capsules

  • Experimental
    SAD:120mg drug group

    On the morning of D1, the patients took 120mg of hydronidone capsules orally on an empty stomach once.

    Drug: Hydronidone capsules

  • Experimental
    SAD:240mg drug group

    On the morning of D1, the patients took 240mg of hydronidone capsules orally on an empty stomach once.

    Drug: Hydronidone capsules

  • Experimental
    SAD:300mg drug group

    On the morning of D1, the patients took 300mg of hydronidone capsules orally on an empty stomach once.

    Drug: Hydronidone capsules

  • Experimental
    SAD:360mg drug group

    On the morning of D1, the patients took 360mg of hydronidone capsules orally on an empty stomach once.

    Drug: Hydronidone capsules

  • Experimental
    SAD:420mg drug group

    On the morning of D1, the patients took 420mg of hydronidone capsules orally on an empty stomach once.

    Drug: Hydronidone capsules

  • Experimental
    MAD: drug group1 (dosage to be determined)

    Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.

    Drug: Hydronidone capsules

  • Experimental
    MAD: drug group 2 (dosage to be determined)

    Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.

    Drug: Hydronidone capsules

  • Experimental
    MAD: drug group 3 (dosage to be determined)

    Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.

    Drug: Hydronidone capsules

  • Experimental
    Study on the Interaction between Food and Drugs:drug group1 (dosage to be determined)

    Period 1 involved administration under fasting conditions, with a 7-day washout period starting on Day 2. Administration for Period 2 was conducted on Day 8.

    Drug: Hydronidone capsules

  • Experimental
    Study on the Interaction between Food and Drugs:drug group2 (dosage to be determined)

    In Period 1, a high-fat meal was consumed first, followed by drug administration within 30 minutes, with washout commencing on Day 2. After a total 7-day washout period, the second period of dosing was administered on Day 8.

    Drug: Hydronidone capsules

  • Placebo comparator
    SAD:Placebo group

    On the morning of D1, the patients took 180mg of hydronidone capsules orally on an empty stomach once.

    Drug: Placebo capsules

  • Placebo comparator
    MAD:Placebo group

    Single dose on an empty stomach on Days 1 and 8; on Days 2-7, take oral medication once every 8 hours.

    Drug: Placebo capsules

Interventions

  • SAD:Single-dose administration MAD:Multiple-dose group Study on the Interaction between Food and Drugs

  • DrugPlacebo capsules

    SAD:Single-dose administration MAD:Multiple-dose group Study on the Interaction between Food and Drugs

06

What researchers measure

Primary outcomes

  1. SAD :Blood drug PK parameters(Cmax)

    Time frame: 24 hours after administration

  2. SAD:Blood drug PK parameters(Tmax)

    Time frame: 24 hours after administration

  3. SAD:Blood drug PK parameters(AUC0-t)

    Time frame: 24 hours after administration

  4. SAD:Blood drug PK parameters( t1/2)

    Time frame: 24 hours after administration

  5. SAD:Blood drug PK parameters(AUC0-∞)

    Time frame: 24 hours after administration

  6. SAD:Blood drug PK parameters(λz)

    Time frame: 24 hours after administration

  7. SAD:Blood drug PK parameters(Vd/F)

    Time frame: 24 hours after administration

  8. SAD:Blood drug PK parameters(CL/F)

    Time frame: 24 hours after administration

  9. SAD:Blood drug PK parameters(AUC_%Extrap)

    Time frame: 24 hours after administration

  10. SAD:Blood drug PK parameters(MRT)

    Time frame: 24 hours after administration

  11. MAD:Blood drug PK parameters(ss)

    Time frame: 24 hours after administration

  12. MAD :Blood drug PK parameters(Cmax)

    Time frame: 24 hours after administration

  13. MAD:Blood drug PK parameters(Tmax)

    Time frame: 24 hours after administration

  14. MAD:Blood drug PK parameters(AUC0-t)

    Time frame: 24 hours after administration

  15. MAD:Blood drug PK parameters( t1/2)

    Time frame: 24 hours after administration

  16. MAD:Blood drug PK parameters(AUC0-∞)

    Time frame: 24 hours after administration

  17. MAD:Blood drug PK parameters(λz)

    Time frame: 24 hours after administration

  18. MAD:Blood drug PK parameters(Vd/F)

    Time frame: 24 hours after administration

  19. MAD:Blood drug PK parameters(CL/F)

    Time frame: 24 hours after administration

  20. MAD:Blood drug PK parameters(AUC_%Extrap)

    Time frame: 24 hours after administration

  21. MAD:Blood drug PK parameters(MRT)

    Time frame: 24 hours after administration

  22. The influence of food on the parameters of single-dose pharmacokinetics(Tlag)

    Time frame: 24 hours after administration

  23. The influence of food on the parameters of single-dose pharmacokinetics(Cmax)

    Time frame: 24 hours after administration

  24. The influence of food on the parameters of single-dose pharmacokinetics(Tmax)

    Time frame: 24 hours after administration

  25. The influence of food on the parameters of single-dose pharmacokinetics(AUC0-t)

    Time frame: 24 hours after administration

  26. The influence of food on the parameters of single-dose pharmacokinetics(AUC0-∞)

    Time frame: 24 hours after administration

Secondary outcomes

  1. Hydronidone and its metabolites M3 and M4 blood drug concentrations (SAD)

    Time frame: 24 hours after administration

  2. Hydronidone and its metabolites M3 and M4 blood drug concentrations (MAD)

    Time frame: 24 hours after administration

  3. Safety indicator: Any adverse event

    Adverse Event (AE) is defined as any untoward medical occurrence during drug clinical trials, drug therapy, or medical procedures, regardless of its causal relationship to the drug used.

    Time frame: 48 hours after administration

  4. Safety indicators:Chest X-ray examination

    Time frame: 48 hours after administration

  5. Safety indicators:12-lead electrocardiogram examination.

    The 12-lead electrocardiogram records the electrical activity of the heart through 12 different lead positions, and is the most commonly used and fundamental non-invasive examination method for diagnosing heart diseases.A 12-lead ECG examines P waves, PR intervals, QRS complexes, ST segments, T waves, QT intervals, and other ECG waves and intervals.

    Time frame: 48 hours after administration

07

Study locations

1 site
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in May 2026, 5 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 3, 2025
StartActual
Dec 24, 2025
Primary completionActual
May 28, 2026
CompletionActual
May 28, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07262346
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Dec 24, 2025
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Sep 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion